In order to test whether the TLR7/8 agonist R848 could reverse this, we began by first identifying pDCs from AML patients and from healthy donor PBMCs (Lin˗/HLA-DR+/CD123+/BDCA2+, Figure 1A). Here, TLR7 is linked to acute myeloid leukemia.